Peer-Review ""Failures""

I applaud NIH's examination of the peer review process (The Scientist, August 8, page 1) and the agency's attempt at procedural reforms aimed at funding the best possible science. At bottom, much of the concern with the peer-review system at NIH, as with professional journals, lies in the inescapable fact that the same small pool of experts serves as both reviewer and reviewee for an extended time in many domains, facilitating two inappropriate practices—backslapping and backbiting. The sm

Written byWilliam Cooper
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The plan to look at NIH peer review's "rate of failure" by a retrospective examination of scientific advances and their funding will help identify projects that typically succeeded in obtaining funding elsewhere. However, the study cannot estimate the extent of review failure that might be attributable to premature departure from the field of promising investigators who had been denied NIH funding. The potential discoveries of such individuals remain as incalculable as the potential discoveries of buried soldiers. Some rough estimation of this area of failure might be obtained if the study could be augmented by an examination of the current performance and attitudes of such former investigators. But because science itself addresses the unknown and because only a small proportion of research projects bear a significant impact on the future course of discovery, we can never be certain that a particular system of peer review or a particular set of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies